ARS Pharmaceuticals Analysts Cut Their Forecasts After Downbeat Q3 Results
ARS Pharma missed Q3 earnings and sales estimates; shares rose 5.6% premarket as analysts cut price targets despite neffy progress.
Share
Why It Matters
ARS Pharma missed its sales and profit targets last quarter. Even though analysts lowered their forecasts, investors seemed okay with the company's progress so far.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.